Pacira | PCRX - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
Astellas Pharma JPY 3.91B 320M 2025-03
Bristol-Myers Squibb USD 411M 21M 2026-03
Cara Therapeutics -89.64M 128.67M 2025-12
Coherus Biosciences USD 2.25M 76K 2025-12
Heron Therapeutics USD 600K 100K 2024-12
Ironwood Pharmaceuticals USD 8.74M 506K 2024-12
J&J USD 43M 25M 2026-03
Ligand Pharmaceuticals USD 1.78M 875K 2025-12
Nektar Therapeutics USD 9.77M 3.75M 2025-12
Novo Nordisk DKK 1.53B 3.43B 2025-09
Omeros USD 4.05M 5.16M 2024-09
Pacira USD 3.7M 193K 2026-03
Perrigo USD 7.98B 7.94B 2026-03
Pfizer USD 671M 40M 2026-03
Supernus Pharmaceuticals USD 910K 278K 2023-06
Teva Pharmaceutical Industries USD 216M 4M 2026-03
Xeris Pharmaceuticals USD 6.88M 269K 2026-03
Xoma USD 3.4M 150K 2024-06
Zoetis USD 62M 5M 2026-03